41 results
424B5
PRQR
ProQR Therapeutics N.V
24 Apr 23
Prospectus supplement for primary offering
4:30pm
of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors; and
general economic, industry and market conditions
6-K
EX-99.3
PRQR
ProQR Therapeutics N.V
18 Apr 23
Current report (foreign)
8:05am
Pharmaceuticals and Baxter Healthcare. Ms. Heggie has also been a board member at SOBI (Swedish Orphan Biovitrum) and currently serves on the board of BioCryst
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
18 Apr 23
Current report (foreign)
8:05am
held increasingly senior positions in the commercial organizations at Janssen Pharmaceuticals and Baxter Healthcare. She previously served
F-3
PRQR
ProQR Therapeutics N.V
29 Mar 23
Shelf registration (foreign)
4:53pm
of our ordinary shares by us, our insiders or our other shareholders;
changes in the structure of healthcare payment systems;
market conditions
6-K
EX-10.1
p214ghv2w3 jd
23 Dec 22
Current report (foreign)
7:10am
6-K
blr8ui gtk
9 Nov 22
Current report (foreign)
7:03am
6-K
EX-99.2
yts925fk
9 Nov 22
Current report (foreign)
7:03am
6-K
EX-99.1
ledl3p40 82p9
30 Dec 21
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
7:19am
424B5
3zit ty92z47uegdg
17 Nov 21
Prospectus supplement for primary offering
4:47pm
424B5
2cuv6gctcvu4mipecjq4
17 Nov 21
Prospectus supplement for primary offering
4:45pm
F-3
3k9 avpryb30c
4 Nov 21
Shelf registration (foreign)
5:02pm
F-3
t6b7lo v3xbyag
4 Nov 21
Shelf registration (foreign)
4:58pm
6-K
EX-10.1
guepq
8 Sep 21
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
4:10pm
424B5
udd8gpxc8v7
1 Apr 21
Prospectus supplement for primary offering
5:17pm
424B5
9o4zh5r rp5imk1bj
1 Apr 21
Prospectus supplement for primary offering
5:14pm
424B5
zxdpq6pcf 4h6hwhrnew
30 Mar 21
Prospectus supplement for primary offering
12:00am